HER-2 directed therapies across gastrointestinal tract cancers – A new frontier
Cancer Treatment Reviews · 2024-09 · 129 · 102789
DOI: 10.1016/j.ctrv.2024.102789 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-09. Verfasst von Lauren Jones und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London, Sutton, UK. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London, Sutton, UK.
- Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London, Sutton, UK. Electronic address: Naureen.starling@rmh.nhs.uk.
Zitieren
APA
Jones, L., Cunningham, D., & Starling, N. (2024). HER-2 directed therapies across gastrointestinal tract cancers – A new frontier. Cancer Treatment Reviews, 129, 102789. https://doi.org/10.1016/j.ctrv.2024.102789
Vancouver
Jones L, Cunningham D, Starling N. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier. Cancer Treatment Reviews. 2024;129:102789. doi:10.1016/j.ctrv.2024.102789
BibTeX
@article{Jones2024,
author = {Jones, Lauren and Cunningham, David and Starling, Naureen},
title = {HER-2 directed therapies across gastrointestinal tract cancers – A new frontier},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {129},
pages = {102789},
doi = {10.1016/j.ctrv.2024.102789}
}
EUVIMED